Luvixasertib
CAS No. : 1610759-22-2
(Synonyms: CFI-402257)
| Size | Price | Stock |
|---|---|---|
| 5mg | $190 | In-stock |
| 10mg | $270 | In-stock |
| 25mg | $490 | In-stock |
| 50mg | $730 | In-stock |
| 100mg | $970 | In-stock |
| 200 mg | Get quote | |
| 500 mg | Get quote | |
| We match the lowest price on market. | ||
We offer a substantial discount on larger orders, please inquire via [email protected]
or Fax: (86)21-58955996
Inquiry for price and availability only. Please place your order via our email or fax.
| Cat. No. : | HY-101340 |
| M.Wt: | 498.58 |
| Formula: | C28H30N6O3 |
| Purity: | >98 % |
| Solubility: | DMSO : 1.67 mg/mL (ultrasonic) |
CFI-402257 is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 has anti-cancer activity[1].
IC50 & Target:IC50: 1.7 nM (TTK in vitro)[1].
In Vitro: CFI-402257 is highly selective to TTK. CFI-402257 is tested against a panel of human kinases at 1 μM and inhibits none of the 262 kinases tested. CFI-402257 is a potent inhibitor of cell growth[1].
CFI-402257 (200 nM, 6 h) causes a massive increase in chromosome missegregations[2].
CFI-402257 (0, 50 or 100 nM) induces a dose-dependent dysregulation of the cell cycle, resulting in an increase in the frequency of cells exhibiting an aneuploid DNA content[2].
In Vivo: CFI-402257 given orally QD shows dose-dependent activity in mice with established tumors from xenografted MDA-MB-231 human TNBC cells and MDA-MB-468 human TNBC cells in mice. CFI-402257 demonstrates antitumor activity in a platinum-resistant PDX model of high-grade serous ovarian cancer[2].
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Autem earum hic iste maiores, nam neque rem suscipit. Adipisci consequatur error exercitationem fugit ipsam optio qui, quibusdam repellendus sed vero! Debitis.
Inquiry Information- Product Name:
- Luvixasertib
- Cat. No.:
- HY-101340
- Quantity:
Your information is safe with us.